Last reviewed · How we verify
FB825
FB825 is a small molecule that targets the SGLT2 receptor.
FB825 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | FB825 |
|---|---|
| Sponsor | Oneness Biotech Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, FB825 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma (PHASE2)
- Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults (PHASE1)
- Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis (PHASE2)
- Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis (PHASE2)
- An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis (PHASE2)
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FB825 CI brief — competitive landscape report
- FB825 updates RSS · CI watch RSS
- Oneness Biotech Co., Ltd. portfolio CI